Novartis to scale up data science under AI deal with Oxford

Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Oxford's Big Data Institute (BDI) will use artificial intelligence to analyze ultra large and multiple data sets from Novartis' drug development programs to identify early predictors of patient response to treatments.

Under the five-year deal, the partners will apply BDI's statistical machine learning technology and advanced analytics to anonymized data from Novartis' clinical trials as well as from about 5 million patients from the U.K. and BDI's international partner organizations. Novartis said the deal will be transformative for how the pharma adopts data science at scale from multiple data sources to understand complex diseases and improve drug development...